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Views and Perspectives
Delay in OnabotulinumtoxinA Treatment During  
the COVID-19 Pandemic-Perspectives from a Virus Hotspot
Ashhar Ali, DO
The COVID-19 pandemic has undoubtedly changed our practice of medicine. With our collective resources and attention 
focused on caring for those afflicted with the disease, other medical conditions have temporarily but understandably faced 
constraint. For migraine patients who often require in-person visits for infusions and procedures, this has become particularly 
challenging. Here, we share our experience in navigating this exigency amidst a local surge of COVID-19.
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BACKGROUND
Due to the COVID-19 pandemic, many medical 
centers have opted to close all outpatient clinics and 
procedures to mitigate the impact of this disease. Such 
closures have either occurred out of caution, to protect 
patients and providers from exposure to the disease 
by means of social distancing, or due to limitation of 
resources, as outpatient healthcare providers including 
physicians, advanced practice providers, and support 
staff  have been redeployed to emergency departments 
and inpatient units. In addition, with the limited avail-
ability of personal protective equipment (PPE), pro-
cedures and elective surgeries have been postponed to 
preserve PPE for COVID-19 care.
As a result, in virus hotspots such as New York 
City, New Orleans, and here in Detroit, non-emergent 
medical visits and procedures, such as biopsies and 
non-time-sensitive surgeries, have been postponed. 
It has become particularly challenging for migraine 
patients that live in and around these hotspots.
TRANSITIONING TO VIRTUAL CARE
Clinical providers across the country have had 
to adjust practice styles by converting in person vis-
its to remote visits using video technology or tel-
ephone. Within the neurological subspecialties, it is 
perhaps Headache Medicine that has best adapted 
to this change, as the diagnosis of headache disor-
ders is largely based on a patient’s history. Treatments 
including oral and injectable medications can safely 
be prescribed to local pharmacies that offer drive-thru 
services, and in many cases, free home-delivery. While 
the exclusion of secondary causes of headache requires 
comprehensive neurological examination and, at times, 
diagnostic testing, it may not be time-sensitive in 
patients with chronic headache.
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With a steep learning curve, it has taken weeks to 
adjust to this transition, but with time and diligence 
we have seen tremendous progress. However, our main 
challenge has been the delay and/or cancelation of 
in-person migraine treatment.
POSTPONING ONABUTLINUMTOXINA 
PROCEDURES IN THE ERA OF COVID-19: 
OUR EXPERIENCE
Here in southeast Michigan, treatment of headache 
had to evolve as a result of this pandemic. Inpatient 
admissions for intravenous (IV) dihydroergotamine, 
outpatient infusion therapies, and procedures such as 
pericranial nerve blocks have been on hold due to the 
active surge of COVID-19 patients. Perhaps most chal-
lenging for patients and headache providers alike is the 
delay in the administration of botulinum toxin injec-
tions for patients with chronic migraine. This is a popu-
lation that has often suffered for years. They have had 
to fail numerous non-FDA approved preventive thera-
pies due to insurance restrictions in order to be offered 
onabotulinumtoxinA, which until the spring of 2018 
was the only FDA-approved treatment for chronic mi-
graine. And, outside of this pandemic, even a 1-2 week 
delay in a treatment is challenging and at times disa-
bling for a person with chronic migraine. Hence many 
of our patients have become comfortable with and reli-
ant upon their quarterly treatments and are not pre-
pared for a disruption.
Suspecting that a delay may not be well-received 
by some of our patients, we at our headache clinic have 
proactively offered video visits in place of their onabot-
ulinumtoxinA treatment. The intent behind this was 
2-fold: (1) to review their migraine care and develop 
a strategy to manage a flare of their chronic migraine 
(2) to reassure them that we are with them in their 
struggle and that their migraine care is as important as 
any other health condition.
During these video visits, we tailor a short-term 
care plan using various treatments. These include 
many of the “bridge” strategies highlighted by the re-
cent Szperka et al publication to help break a severe 
or continuous pain cycle.1 Additional treatments that 
have been offered include short courses of oral corti-
costeroids, a temporary increase in the dose of exist-
ing oral prophylactic treatment, transitioning (perhaps 
temporarily) to a monoclonal cGRP antibody, and tri-
als of neuromodulation devices.
The 3 recent cases are illustrated below. All patients 
have been receiving the FDA-approved PREEMPT 
protocol for chronic migraine. They were seen via vir-
tual video visits between March 30th, 2020, and April 
10th, 2020.
Case 1.—A 46-year-old female has been responding 
well to quarterly onabotulinumtoxinA injections since 
late 2017. Her acute therapy has been combination 
sumatriptan/naproxen. She raised concerns about 
using an NSAID during this pandemic that has been cit-
ed (but since been refuted by the World Health Organi-
zation and European Medicines Agency) as potentially 
worsening COVID-19.2,3 She preferred to avoid all 
NSAIDs, and thus we changed her acute therapy to 
rizatriptan. She was prescribed chlorzoxazone to use 
as needed during the daytime for breakthrough pain. 
A short-term preventive with tizanidine at bedtime was 
also started. She was very appreciative of the consul-
tation and provided words of encouragement to our 
healthcare team during this crisis.
Case 2.—A 26-year-old female with chronic 
migraine for 1 year, previously with episodic migraine, 
received her 1st onabotulinumtoxinA treatment in Jan-
uary of 2020. Following this initial treatment, she had 
a 50% improvement in both migraine severity and fre-
quency. During the video visit, she raised significant 
concern about any delay in her onabotulinumtoxinA 
treatment. She contacted a neurologist’s office ap-
proximately 90 miles away, outside the COVID-19 
hotspot of southeast Michigan, and was able to be 
scheduled for her next treatment 2 days later. We facil-
itated transfer of records and authorization. She was 
appreciative of our support and willingness to facili-
tate her temporary care outside of our clinic. She will 
resume her next onabotulinumtoxinA treatment with 
us as this active surge subsides.
Case 3.—A 35-year-old female has received 2 botu-
linum toxin injection treatments since the fall of 2019. 
Since her 2nd treatment, she had only 1 migraine. 
Overall, she reports a 95%-100% improvement in 
migraine frequency and severity. She expressed grave 
concern regarding a delay in her onabotulinumtoxi-
nA treatment. She had just passed the 12 week mark 
since her last treatment and has already noticed 
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daily mild non-migrainous headache. She endorses 
tremendous anxiety about the delay and questions 
why, from her perspective, a medically necessary and 
time-sensitive treatment has to be delayed. We ac-
knowledged her concerns and empathized with her. 
We proceeded to develop a short-term treatment plan. 
She was provided with a methylprednisolone dose 
pack, and her prophylactic treatment, nortriptyline, 
was increased to 50  mg nightly. She was also started 
on tizanidine every 8 hours. We ended the visit by reas-
suring her that her medical condition is a priority for 
us and that we would resume her onabotulinumtoxinA 
treatment as soon as safely possible. By the end of the 
visit, she was appreciative of the visit and gesture.
REFLECTIONS
The virtual visit experience has been humbling. 
Most patients that we have reached out to have been 
willing to delay their onabotulinumtoxinA treatment 
given the circumstances, especially when the treat-
ing provider directly reaches out to the patient. It 
appears that most do recognize the risks of exposure 
to COVID-19 with any mutual contact particularly in 
a healthcare setting and want to do their part in pre-
venting the spread of this disease. Often this is supple-
mented with words of support for those of us on the 
frontlines, who are juggling between our traditional 
outpatient duties in caring for the migraine population 
and our newly assigned frontline duties that include 
direct care of COVID-19 patients. They are satisfied 
with the “bridge” plan and often end their visit by shar-
ing words of encouragement and reminding us health-
care providers to stay safe and well.
Few patients have expressed anxiety coupled with 
frustration. There is anxiety about delaying a treatment 
that has been so effective for them for so long. There 
is frustration that perhaps their medical condition is 
being minimized in light of this pandemic. It yields 
a response of, “well, what about my migraine?” or “I 
get that COVID-19 is priority, but why is my condi-
tion being ignored?” In these situations, we have found 
it helpful to simply acknowledge their concerns and 
worries rather than challenge it. Ultimately, chronic 
migraine is disabling, and botulinum toxin injections 
have repeatedly been shown to improve migraine-related 
disability and quality of life.4-6 Further, we do see that 
COVID-19 is unlikely to cause significant complica-
tions in our greater migraine population which consists 
of young, healthy women.7,8 Hence, from the perspec-
tive of the patient, 1 can understand why feelings of 
appreciation may be mixed with feelings of worry, frus-
tration, and a sense of neglect. And by acknowledging 
the concerns and emotions, by demonstrating our sup-
port for them through proactively scheduled tele-visits, 
and by providing a backup “bridge” treatment plan, we 
feel we have been able to better navigate this challenge.
CONCLUSION
As this virus continues to spread and other 
so-called hotspots are formed, novel strategies to 
facilitate the care of  our migraine patients, particularly 
those that come in regularly for procedures or infu-
sions, will need to be carefully thought out. This pan-
demic has evolved, and it now appears that COVID-19 
will be with us for some time. Our migraine patients 
need to hear from us, perhaps now more than before, 
that they too are priority and that their care will not 
be neglected or brushed aside, be it during this time of 
crisis or in the future. Hearing this directly from us will 
go a long way.
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